Zacks Research Issues Optimistic Forecast for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for Halozyme Therapeutics in a research report issued to clients and investors on Tuesday, January 7th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings per share of $0.98 for the quarter, up from their previous estimate of $0.97. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2025 earnings at $1.33 EPS, FY2025 earnings at $4.50 EPS, Q3 2026 earnings at $1.38 EPS and Q4 2026 earnings at $1.63 EPS.

Several other brokerages have also recently commented on HALO. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $68.00 price target on shares of Halozyme Therapeutics in a research note on Monday, December 30th. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $58.00 to $62.00 in a report on Monday, October 7th. Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Finally, JMP Securities raised their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.11.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $53.76 on Thursday. Halozyme Therapeutics has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The stock’s 50-day moving average is $50.10 and its two-hundred day moving average is $54.00. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm has a market cap of $6.84 billion, a P/E ratio of 17.80, a PEG ratio of 0.44 and a beta of 1.24.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of HALO. Verdence Capital Advisors LLC grew its position in Halozyme Therapeutics by 1.9% in the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock worth $757,000 after purchasing an additional 252 shares during the last quarter. GAMMA Investing LLC grew its position in Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 350 shares in the last quarter. Private Advisor Group LLC increased its stake in Halozyme Therapeutics by 1.8% during the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company’s stock valued at $1,191,000 after acquiring an additional 412 shares during the period. Juncture Wealth Strategies LLC raised its holdings in Halozyme Therapeutics by 3.6% in the 3rd quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock valued at $690,000 after acquiring an additional 415 shares in the last quarter. Finally, Diversify Advisory Services LLC grew its holdings in shares of Halozyme Therapeutics by 8.5% during the 3rd quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 418 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the transaction, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $9,254,244.56. The trade was a 5.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.